Podcast
Author(s):
Melissa A. Simon, MD, MPH, discusses unmet needs regarding clinical trials for underserved populations with cancer, highlights the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shares her advice to health care professionals in the cancer space who are working to bridge some of these disparities.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Melissa A. Simon, MD, MPH, vice chair for research in the Department of Obstetrics and Gynecology, director of the Institute for Public Health and Medicine – Center for Health Equity Transformation, the George H. Gardner, MD, Professor of Clinical Gynecology, and a professor of obstetrics and gynecology (general obstetrics and gynecology)/preventive medicine and medical social sciences at the Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center at Northwestern Medicine.
Simon is also the founding director of the Center for Health Equity Transformation and the Chicago Cancer Health Equity Collaborative, chair of the ECOG-ACRIN Health Equity Committee, and a member of the US Preventive Services Task Force and the National Academy of Medicine’s Roundtable for the Promotion of Health Equity.
During our exclusive interview, Simon discussed unmet needs regarding clinical trials for underserved populations with cancer, highlighted the key objectives of the ECOG-ACRIN Health Equity Committee and the US Preventive Services Task Force, and shared her advice to health care professionals in the cancer space who are working to bridge some of these disparities.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS
2 Commerce Drive
Cranbury, NJ 08512